predominantly TxA 2 and 12-HETE, which are potent vasoconstrictors and platelet-aggregators. Moncada and Vane 2 hypothesized that the balance of TxA 2 and PGI 2 maintained "vascular integrity" consistent with maintenance of the anticoagulated state. This hypothesis also implied that derangements in vascular eicosanoid metabolism could predispose to thrombosis and vasospasm due to the release of procoagulant and vasoactive constituents from platelets and potentially other inflammatory cells. However, it is becoming increasingly apparent that vascular eicosanoids may be implicated in the atherogenic process.
The metabolic derangements leading to smooth muscle cell migration, proliferation, cholesteryl ester deposition, foam cell formation, and eventual plaque development are incompletely understood. Early studies on the pathogenesis of atherosclerosis were carried out by Virchow, 3 who suggested that atherosclerotic lesions form as a consequence of vascular injury. This concept was further extended by Ross et al., 4 who proposed that endothelial denudation elicited mural platelet deposition and secretion of platelet mitogens, which in turn stimulated arterial smooth muscle cell proliferation and accretion of lipid. These pathologic events were postulated to occur in response to a variety of injurious stimuli. 5 Since endothelial denudation and platelet deposition do not normally take place in blood vessels, the response-to-injury hypothesis has now been modified to suggest that alterations in endothelial cell function, perhaps as a result of inflammatory stimuli or other factors, may initiate and mediate the subintimal changes leading to plaque development. 67 ' 8 Evidence implicating eicosanoids in the pathophysiology of atherosclerosis relates to observations that altered eicosanoid metabolism accompanies atherosclerosis. It appears that either a relative deficiency in arachidonic add or defects in arachidonic acid metabolism may occur in atherosclerosis. Patients at risk for myocardial infarction have less arachidonic acid in plasma and tissue than normal. 9 Furthermore, numerous studies 10 -14 have determined that the PGI 2 synthesis is reduced in human, rabbit, and rat atherosclerotic blood vessels during the disease process. Cholesterol feeding also impairs the regeneration of PGI 2 synthetic capacity by neointima (comprised of proliferating endothelial and smooth muscle cells) after balloon catheterization in rabbits. 1516 Diets enriched in polyunsaturated fatty acids (principally linoleic and arachi-donic acids) have been shown to reduce the clinical sequelae of atherosclerotic lesion formation in humans and in animal models. 1718 However, others have shown increased urinary 19 and vascular 2021 PGI 2 production in human and animal atherosclerosis. A number of factors may explain this discrepancy. First, there may be a time-dependent effect of hypercholesterolemia on PGI 2 production, where the onset of cholesterol feeding initially increases, then progressively decreases, vascular PGI 2 production ex vivo. 22 Second, there may be a distinction between tissue capacity to synthesize eicosanoids and actual eicosanoid biosynthetic rates. 23 ' 24 Thus, although total eicosanoid synthetic capacity may be reduced in atherosclerotic disease, a possible state of activation as a result of ischemia or interactions with other cell types, including platelets, as a result of vessel injury may result in increased eicosanoid generation by the diseased tissue. This explanation is also compatible with the temporal effects of hypercholesterolemia on vascular eicosanoid metabolism.
Furthermore, known positive risk factors for atherosclerosis are associated with altered eicosanoid metabolism. Overwhelming evidence suggest that diabetes, a disorder associated with accelerated atherosclerosis, reduces PGI 2 synthesis in rats and other species, 25 -38 although urinary production of PGI 2 and its metabolites may be unchanged 37 or increased and subsequently normalized by insulin treatment. 38 The mechanism by which diabetes inhibits vascular PGI 2 generation may be due to reduction in arachidonate availability to eicosanoid synthetic enzymes, 3234 with no alteration in the activity of PGI 2 synthetase. 39 ' 40 Elevations in urinary PGI 2 metabolites in diabetes may be due to increased PGI 2 production by hypertrophied urinary bladder as a result of the diabetic condition, 41 suggesting that measurements of urinary metabolites of PGI 2 may not reflect an accurate estimate of vascular PGI 2 synthesis. In addition, the effects of diabetes are additive with hypercholesterolemia in inhibiting PGI 2 synthesis from rat aorta. 42 Smoking, a major risk factor for development of atherosclerosis, 43 -* 8 causes reduced vascular eicosanoid synthesis. 47 Aging, which is temporally associated with the incidence and severity of atherosclerosis, is also associated with decreased arterial eicosanoid syntheticcapacity 48 ' 48 ' 60 and increased smooth muscle proliferation. 5152 Viral infection has been implicated as a potential causative factor of atherosclerosis. Viral infection of avian, 5354 bovine, 55 and human 55 arterial smooth muscle cells reduces eicosanoid synthetic capacity and decreases cholesteryl ester hydrolytic activities concomitant with deposition of cholesteryl ester.
Thrombosis, another complication of atherosclerosis, has also been studied in animal models by using inhibitors of cyclooxygenase, such as aspirin. Unfortunately, the results of these studies are contradictory. In some studies, aspirin inhibited the progression of atherosclerosis, 5657 while in another study, aspirin had no beneficial effect. 58 This differential response to cyclooxygenase inhibition may be related to the dose of aspirin, since platelet cyclooxygenase is more sensitive to aspirin inhibition than arterial cyclooxygenase; higher doses of aspirin abrogated the beneficial effect of aspirin seen at lower doses. 59 " 62 Aspirin also ameliorates the recurrence of myocardial infarction in men who have suffered previous myocardial damage. 63 The beneficial effect of aspirin in this setting may be due to stabilization of platelets. 1 -20 Hypertension, which is a major predisposing factor for atherosclerosis, 6465 is associated with increased vascular PGI 2 production, 66 -72 possibly due to increased phospholipase 737475 or PGI 2 synthetase 73 activities. It has been postulated that increased PGI 2 synthesis in hypertension may serve as a compensatory mechanism for the maintenance of arterial tone secondary to increased arterial pressure. 76 However, in spite of increased vascular prostacyclin generation by vascular tissue, the effects of hypertension on plasma prostacyclin are equivocal, with both decreased 77 ' 78 and increased 79 levels of 6-keto-PGF 1a reported in human hypertensive disease. Such observations suggest that eicosanoids may not have an important role in mediating blood pressure regulation in hypertensive disease. This conclusion is reinforced by observations that aspirin does not exacerbate hypertension. It is also important to note that lipid accumulation does not typically occur in hypertension unless there is superimposed hyperlipidemia.
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It is, therefore, possible that mural eicosanoids may be involved in the atherogenic process, although a causeeffect relationship between these two parallel events has yet to be established. Accordingly, the influence of eicosanoids on the ontogeny of the development of the secondary lesion has been an area of extensive study. Eicosanoids have now been implicated in the regulation of the differentiated state of the smooth muscle cells, the migration of medial smooth muscle cells into the subintimal space, and the subsequent proliferation and accumulation of intracellular lipid. The involvement of eicosanoids in these cellular processes is reviewed here.
Role of Eicosanoids in Arterial Smooth
Muscle Cell Function
Smooth Muscle Cell Phenotype
Although the process by which arterial smooth muscle cells change from the contractile to the synthetic phenotype has been reviewed, 81 -84 the cellular mechanisms causing de-differentiation in vascular smooth muscle cells remain obscure. Components of plasma and connective tissue matrix have been implicated. 858887 Normally differentiated arterial smooth muscle cells have abundant thick and thin fibers containing dense bodies, possess little endoplasmic reticulum or Golgi apparatus, 87 and do not respond to mitogens (contractile phenotype). 88 However, de-differentiated (or "modulated") cells have disaggregated actin/myosin filaments, possess an abundant and hypertrophic perinudear microsomal compartment, secrete connective tissue matrix, 8 2 8 3 8 9 9 0 9 1 and respond to mitogens. 88 These cells, which were originally described in vitro, 5 have in vivo counterparts in the atherosclerotic lesion. 9293 Indeed, these may be the cells that have been described historically as progenitor cells in the athero-sclerotic lesion. 94 Since the process of de-differentiation is a major, but insufficient, requirement for cell proliferation, 95 loss of differentiation may be one of the initial events in atherogenesis. 96 Unfortunately, there is relative paucity of data on the role of eicosanoids in mediating the transition in smooth muscle cells from the contractile to the synthetic phenotype. In one carefully done study, modulated arterial smooth muscle cells synthesized more PGI 2 de novo than did contractile smooth muscle cells. 97 In another study, exogenously added prostaglandin E, (PGE,), which has biological properties similar to PGI 2 , stimulated the transition from contractile to synthetic phenotype. 88 However, the cause-effect relationship between eicosanoids and the differentiated state in smooth muscle cells remains obscure.
Smooth Muscle Cell Mlgratlon/Chemotaxls
In response to injury, modulated cells migrate into the subintimal space. 12-HETE, which is synthesized by stimulated platelets even in the presence of aspirin and, to a lesser extent, by endothelial cells, is the most potent chemotactic HETE, with 15-HETE having less activity; 5-HETE is not active in this regard. 96 This activity is calcium dependent, since the calcium ionophore, A-23187, induced cell migration, which was inhibited by calciumchannel blockers. 100 It should be noted that these studies were performed in a serum-replete system; consequently, the actual amount of 12-HETE evaluated in these studies may have been substantially underestimated. There appears to be a developmental aspect to this phenomenon; smooth muscle cells from aged rats are not only more proliferate than smooth muscle cells from young rats, but also exhibit greater chemotaxis in response to 12-HETE. 101 Leukotriene B 4 (LTB 4 ) (a neutrophil lipoxygenase product) is also chemotactic, but not chemokinetic, for arterial smooth muscle cells.
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These data have implications from the standpoint of cell-to-cell interactions, since both endogenous, and neutrophil-, platelet-, and endothelial cell-derived eicosanoids may have significant effects on smooth muscle cell migration. Unfortunately, no data are currently available on the effects of PGI 2 , Tx A 2 , or the surfidopeptidecontaining eicosanoids (LTC 4 , LTD 4 , or LTE 4 ) on smooth muscle cell migration. These data suggest that activated endothelial cells, platelets, neutrophils, and macrophages are capable of eliciting smooth muscle cell migration (a component of vascular inflammation) into the area of injury via endogenously synthesized eicosanoids.
Smooth Muscle Cell Proliferation
The effects of the precursor compound, arachidonic acid, on arterial smooth muscle cell proliferation is unclear. In one study, arachidonic acid inhibited smooth muscle cell proliferation independent of PGI 2 biosynthesis, suggesting that inhibition of smooth muscle cell growth was due to other fatty acid components or to lipid peroxides. 103 However, in a later study, the same group reported that arachidonate stimulated the proliferation of smooth muscle cells that was correlated with and dependent upon PGI 2 biosynthesis. 104 Thus, the initial study must be confirmed. These findings suggest that oxidized metabolites of arachidonate or other fatty acids can affect cell proliferation 105 ; however, the conflicting results concerning the effects of arachidonate on smooth muscle cell proliferation may be a function of the dose used in each study or of the nonspecific detergent effects of the fatty acid.
There have been studies which have shown that PGI 2 inhibits the proliferation of arterial smooth muscle cells in vivo, 108 presumably by inhibiting platelet activation and secretion of platelet products known to stimulate endothelial and smooth muscle cell PGI 2 generation (see below) and in vitro by inhibiting DNA synthesis. 107 However, proliferating cells also synthesize more PGI 2 than quiescent cells.
97 PGE, (an eicosanoid synthesized from dihomogamma-linoleic acid) inhibits smooth muscle cell growth directly but only at the G-1 phase of the cell cycle via stimulation of cyclic 3',5'-adenosine monophosphate (cAMP). 108 Once cells progressed into the S-phase, PGE, no longer had an inhibitory effect.
109 These data were corroborated by Nilsson and Olsson, 110 who demonstrated that PGE,, more so than PGE 2 but not PGFa,, inhibited proliferation induced by the platelet-derived growth factor (PDGF) (see below). These data support the concept that endothelial-and smooth muscle cell-derived eicosanoids antagonize and therefore modulate the response to growth factors. 111 These data further suggest that reduction of arterial eicosanoid synthetic capacity may predispose to increased smooth muscle cell proliferation. This hypothesis is supported by observations that aging smooth muscle cells not only synthesize less PGI 2 than do young cells, 4849 but also become more responsive to mitogenic agents such as PDGF.
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The inhibition of cell proliferation appears to be due to increased intracellular cAMP.
108 PGI 2 and PGE, potently stimulate cAMP synthesis in vascular tissue.
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Dipyridamole also increases cAMP and reduces the development of atherosclerosis in rabbits by undefined mechanisms. 115 Since PGI 2 synthetase antigen has been localized in both plasma and nuclear membrane, 116 the ability of PGI 2 to inhibit smooth muscle proliferation may be a direct nuclear event. This concept has yet to be developed experimentally.
The effects of lipoxygenase products on cell proliferation are contradictory. In an in vivo study, dexamethasone, but not indomethacin, prevented chemotaxis and proliferation of smooth muscle cell into the intima in "cuff'-induced atherosclerosis in rabbits. 102 In parallel in vitro studies, LTB 4 , but not 5-or 12-HETE, stimulated arterial cell proliferation, suggesting that LTB 4 is important in mediating the vascular inflammatory response to injury. 102 In contrast, 12-HETE inhibited smooth muscle cell proliferation, 5-HETE and LTB 4 were weakly inhibitory, and TxBj and PGFj,,, were inactive. 117 These data support the concept that neutrophil or monocyte infiltration predisposes to smooth muscle cell proliferation due not only to macrophage-derived peptide growth factors such as PDGF (see below) but also to LTB 4 . vessels concomitant with an increase in mural cholesteryi ester content.
U -UB Although a causal relationship between these two metabolic pathways has been suggested, it has not been proven. Before discussing the role of eicosanoids on cellular cholesterol metabolism, we will describe the cholesteryi ester cycle as it exists in vascular smooth muscle cells.
Briefly, low density lipoprotein (LDL) cholesteryi esters are degraded in the lysosomal compartment after receptormediated endocytosis via acid cholesteryi ester hydrolase (ACEH), and the liberated free cholesterol enters into a cytoplasmic pool. This serves to down-regulate the activity of 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA)-reductase (the committed step in cholesterol biosynthesis from mevalonate). Cytoplasmic free cholesterol also reduces synthesis of the LDL receptor at the level of transcription. Cellular free cholesterol is metabolically active, and its concentration in the cell is rigidly controlled. Excess free cholesterol is stored within the cell as cytoplasmic cholesteryi esters via the enzyme acyl Co A: cholesteryi acyltransferase (ACAT); these cytoplasmic cholesteryi esters may subsequently be hydrolyzed by the cytoplasmic (neutral) cholesteryi ester hydrolase. Free cholesterol may also be translocated to the cell membrane, where it becomes available for removal by high density lipoprotein (HDL) or other plasma (or interstitial) acceptors. This subject has been extensively reviewed. 5 ' 6 Early studies 119 demonstrated that PGE 2 inhibits cholesterol esterification via ACAT in the skin of rats subjected to a diet deficient in essential fatty acids, suggesting for the first time that eicosanoids may modulate cholesteryi ester metabolism. Purified ACAT from either skin or aorta was inhibited dose-dependently by PGE 2 , independent of diet (normal vs. cholesterol-supplemented dj e t)i2o,i2i.i22 in spite of the observation that PGE-, biosynthesis also increased after exposure to an atherogenic diet. 121 In similar studies, PGE 2 inhibited ACAT activity in the aortas of atherosclerosis-resistant Show Racer pigeons but not in the atherosclerosis-susceptible White Cameau pigeons. 123 The mechanism of this apparent sensitivity of the enzyme to inhibition by PGE 2 was not Investigated. 123 Similar findings were also reported: arachidontc acid conversion to PGE 2 was greater in atherosclerosissusceptible White Cameau pigeons. 123 These studies are in contrast to later studies by this group, which demonstrated that PGI 2 synthesis is reduced in other models of atherosclerosis.
1442 Cholesteryi ester hydrolase activity was unaffected by PGE 2 treatment 122 ; however, PGE, slightly inhibited cholesteryi ester hydrolase and ACAT activity. 124 These early experiments, which demonstrated that PGE 2 inhibited cholesterol deposition, although performed by using cellular homogenates or subcellular fractions, provided the background for future research in our laboratory to define the role of eicosanoids In mediating cholesterol metabolism in intact cells. Using intact rabbit aortic smooth muscle cells, we discovered that PGI 2 stimulated lysosomal (acid) cholesteryi ester hydrolase activity by enhancing cAMP levels in these intact arterial smooth muscle cells. This activity was also increased by providing exogenous arachidonic acid (suggesting that endogenously synthesized eicosanoids may mediate the effect) and dibutryl cAMP.
125128 Importantly, the cytoplasmic (neutral) cholesteryi ester hydrolase was also stimulated by PGI 2 via a cAMP-dependent protein kinase mechanism, demonstrating that activation of the cytoplasmic enzyme may occur by covalent pnosphorylation. PGI 2 could also enhance the efflux of the liberated cholesterol from the cell through a cAMP-dependent mechanism.
125128 Etingin et al. 130 extended these studies and demonstrated that other metabolites of PGI 2 , including the dinor and 13,14-dihydro-6,15-diketo-, and 6-15-diketo-PGF 1o derivatives, could stimulate both the acid and neutral cholesteryi ester hydrolases.
Recently our laboratory demonstrated that 12-HETE and 12,20-diHETE also stimulated smooth muscle cell ACEH activity. These eicosanoids did not affect ACAT activity. This reaction resulted in a concomitant reduction in cellular free and esterified cholesterol content. 130 PGE 2 also inhibited ACAT activity (corroborating the above data), but not PGI 2 , 6-keto-PGF 1a , or 6-keto-PGE,. 127 PGE 2 has also been shown to inhibit cholesteryi ester accumulation in macrophages, presumably by Inhibiting ACAT activity. 131 The above data suggest that endogenously synthesized eicosanoids may mediate cholesterol metabolism in intact vessels and also imply that eicosanoids derived from adjacent endothelial cells may mediate alterations in smooth muscle cell cholesteryi ester hydrolytic activities in vivo.
Several years ago, this laboratory showed that cholesteryi esters can accumulate in reendothelized aortic intima in rabbits fed a normocholesterolemic or hyperchclesterolemic diet. 132 - 133 These results suggested that endothelial cells could modulate cholesteryi ester deposition in smooth muscle cells that were present in the adjacent neointima. 132 ' 133 Cholesterol feeding also retarded recovery of neointimal PGI 2 synthetic capacity after balloon deendothelialization in rabbits. 1518 This was corroborated by several in vitro studies, where endothelial cells in co-culture, but not endothelial cell-conditioned media, Influenced smooth muscle cell cholesteryi ester hydrolysis in a time-dependent manner. 134135 The stimulation of lysosomal cholesteryi ester hydrolase activity in smooth muscle cells when co-cultured with endothelial cells was eicosanoid dependent. We observed that endothelial cells initially treated with eicosatetraynoic acid (ETYA, a dual cyclooxygenase and lipoxygenase inhibitor) or aspirin (a cyclcoxygenase inhibitor) inhibited the stimulatory effect on the hydrolase by the endothelial cell. Conditioned media from 48-hour cultures of endothelial cells also stimulated cholesteryi ester hydrolytic activity in the smooth muscle cell, an effect which was inhibited by ETYA, suggesting that lysosomal cholesteryi ester hydrolytic activity was mediated at least in part by stable endothelial cell-derived eicosanoids (6-keto-PGF 1a , PGE 2 , 12-HETE, and 12,20-diHETE). 133 In contrast to these observations in smooth muscle cells, lipoxygenase inhibitors will prevent cholesterol accumulation in macrophages exposed to acetylated LDL, suggesting that macrophage HETE or leukctriene production may promote cholesterol deposition. 138 The effects of eicosanoids on smooth muscle cell cholesterol metabolism are summarized in Figure 1 . Figure 1 . Eicosanoids and the regulation of arterial cholesterol metabolism. Prostacydln (PQI2) and 12-hydroxy-elcosatetraenolc acids (HETE) derived from endothellal and smooth muscle cells stimulate smooth muscle cell lysosomal acid cholesteryl ester hydrolase (ACEH) and cytoplasmic neutral cholesteryl ester hydrolase (NCEH) by cyclic 3',5'-adenosine monophosphate (cAMP) and cAMPdependent protein kinase, respectively. The increase in the activities of these enzymes increases the degradation of cholesteryl esters (CE) derived from low density Hpoprotein (LDL), as well as CE In neutral liptd droplets. Prostaglandin E 2 (PGE 2 ) decreases the activity of acyl-CoA: cholesterol acyltransferase (ACAT), thus facilitating net cholesteryl ester hydrolysis. CHOL=cholesterol, FA=fatty acid.
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In summary, the above data provide a reasonable understanding of the role of eicosanoids (PGI 2 and PGE 2 ) in the promotion of cholesterol efflux by initially hydrolyzing cellular esterified cholesterol to its free form, thereby rendering it accessible to removal from the cell by plasma acceptor particles such as HDL. HETEs may have both a positive and a negative influence on this effect by promoting arachidonate release from membrane phospholipids and by inhibiting cyctooxygenase activity.
Summary
There are experimental data that demonstrate that eicosanoids derived from the arterial wall serve to maintain the cell in a contractile, quiescent, phenotypic state, which is responsive to vasoactive stimuli and not responsive to mitogens. Furthermore, endogenously synthesized eicosanoids help to maintain cellular cholesterol content at a low level. However, eicosanoids derived from monocytes and neutrophils may promote the inflammatory response by promoting smooth muscle cell modulation to the synthetic phenotype and promoting smooth muscle ceil migration, proliferation, and cholesteryl ester deposition. This raises the possibility that mural eicosanoids are antiatherogenic, while eicosanoids derived from inflammatory cells may initiate or mediate the processes leading to plaque development. The data are summarized in Table 1 .
Factors Modulating Arterial Smooth Muscle Cell Proliferation, Cholesterol Metabolism, and Elcosanold Biosynthesis
Plasma Llpoprotelns
The effects of LDL on eicosanokJ metabolism in vascular tissue are undefined. Early studies by Nordoy et al. 137 demonstrated that high concentrations of LDL inhibited the platelet-antiaggregatory activity derived from human umbilical venous endothelial cells. The major source of this activity was thought to be PGI 2 . 138138 However, in subsequent studies the same group found that very low density Hpoprotein (VLDL) and LDL had no effect on PGI 2 generation. 140 Even though eicosanoid metabolism was not augmented in these experiments, these llpoproteins did stimulate endothelial cell synthesis of apolipoprotein (apo) A-1, the principal apoprotein of HDL. 140 However, in subsequent research, native LDL was shown to stimulate eicosanoid production in endothelial and smooth muscle cells.
141142 ' 143 The mechanism(s) by which LDL induced eicosanoid production are unclear, but may be due to enhanced substrate availability. 141 This is in accord with the observations by Hartung et al., 144 who demonstrated that acute stimulation of the scavenger receptor by acetylated or malondialdehyde-modified LDL promotes eicosanoid generation in monocyte/macrophage populations. These results suggest that activation of phospholipase A 2 may also be a feature of LDL-induced PGI 2 generation in the absence of cholesterol enrichment. It has been further proposed 145 that the mechanism by which LDL decreases eicosanoid production involves free radical-mediated destruction of eicosanoid-synthetic enzymes by lipid peroxides artifactually generated during purification of LDL from plasma This is based on observations that LDL oxidized by exposure to agents such as copper or by exposure to either endothelial cells or macrophages 148 -151 contains lipid peroxides, 152 which are thought to decrease eicosanoid production. 153 This is a significant finding, since 15-HPETE is a major HETE product of the atherosclerotic vessel wall 154 and inhibits vascular PGI 2 synthetase. 155 In any case, the role of LDL on cellular eicosanoid generation remains to be completely elucidated.
In contrast, plasma HDL is the most active of the cholesterol acceptor molecules in plasma 156157158 HDL actually promotes net cholesterol efflux from all cells studied, including vascular smooth muscle cells, 157 -181 fibroblasts, 1 5 6 1 6 1 -1 6 5 macrophages, 1 8 6 1 6 7 1 6 8 and endothelium. 188 HDL is thought to be the major carrier of cholesterol from peripheral tissue to the liver for ultimate excretion (i.e., "reverse cholesterol transport" 163170 ).
Importantly, these findings may have clinical relevance, since high plasma HDL levels are inversely related to the incidence and severity of atherosclerosis.
171172 This is supported by additional studies. We and others have demonstrated that HDL stimulates eicosanoid production from a variety of cell types in several model systems. HDL induces PGI 2 production in vascular endothelial cellsi4o.i42.i73.i74 smooth muscle cells, 141 and isolated perfused rabbit hearts.
175176 HDL-induced eicosanoid production originates from arachidonate of HDL cholesteryl esters or phospholipid pools that are phospholipasesensitive and accessible to cyclooxygenase. 141142 In addition, HDL stimulates the mobilization of cellular arachidonic acid. This suggests that HDL increases turnover of arachidonic acid in cellular phospholipid pools.
141142 '
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The requirement of HDL for endothelial and smooth muscle viability 177 may, in part, be mediated through its ability to remove excess cellular cholesterol. In fact, HDL-induced cholesterol efflux may be mediated, at least in part, by endogenous eicosanoid production.
Studies with cultured cells have been performed to elucidate mechanisms of altered eicosanoid metabolism induced by cholesterol enrichment. These have been derived either from cholesterol-fed animals or by enrichment with cholesterol in vitro. Eicosanoid metabolism is a function of substrate availability from plasma, 178179180 activity of high affinity uptake mechanisms for arachidonic acid, 181 intracellular substrate availability to cellular phospholipases, 23105 and the activity of phospholipases and "distal" enzymes from the rate-limiting step in the metabolic cascade, such as PGI 2 synthetase. Conceivably, alterations in any of the above could result in altered eicosanoid metabolism after cholesterol enrichment. In fact, cultured smooth muscle cells and endothelial cells derived from human atherosclerotic aortas demonstrate reduced capacity for synthesis of PGI 2 and PGE 2 from either exogenous or endogenous arachidonic ac jd.i3,iB2,i83,is4 However, the mechanism of this phenomenon is not known.
Cholesterol-enriched smooth muscle cells synthesize less eicosanoids, but again the mechanism is unclear. 185 Our laboratory has demonstrated that cholesterolenriched cells synthesize less eicosanoids by at least two mechanisms. The first is inhibition of phospholipase A 2 by linoleate in LDL cholesteryl esters. The latter is hydrolyzed in the lysosomal compartment of the cell and becomes incorporated into the phospholipid compartment. As phospholipid, it competes at the level of phospholipase A 2 for release and conversion to eicosanoids. This finding is reinforced by data demonstrating that linoleate and other fatty acids can compete with arachidonate for incorporation into cell phospholipids and can inhibit endothelial and smooth muscle cell eicosanoid metabolism. 186 - 189 The second mechanism is direct inhibition of phospholipase A 2 by cholesterol. 190 This finding supports previous observations that cholesterol can directly inhibit phospholipase A 2 in fibroblasts, 191 presumably by altering membrane fluidity.
The effects of cholesterol enrichment on macrophage eicosanoid metabolism are not yet clarified. Oxidized LDL augments arachidonic acid metabolism by stimulation of phospholipase A 2 in macrophages, but not in fibroblasts. 192 Similarly, Mathur and Reid 193 demonstrated that cholesterol enrichment increased release of arachidonate and its metabolism to 12-HETE and thence to di-HETEs. In contrast, Saito et al. 194 have shown that peripheral blood monocytes from cholesterol-fed rabbits exhibited reduced eicosanoid biosynthesis. One explanation for this discrepancy may relate to the time frame of the study. We suggest that linoleate from LDL cholesteryl esters is incorporated into cellular phospholipids, which initially increases eicosanoid biosynthesis as arachidonate is mobilized into other cell lipkj pools and into eicosanoid biosynthesis rather than being re-incorporated into cellular phospholip-ids due to competition by linoleate. Eventually, eicosanoid synthesis would be reduced because of a decrease in the arachidonate/linoleate ratio in cell phospholipids and the subsequent decrease in substrate availability.
The role of eicosanoids in the regulation of cholesterol efflux requires further study. Singh et al. 185 - 185 have shown that acute stimulation of endogenous eicosanoid production or exogenously added PGE 2 or 6-keto-PGF 1o does not alter the incorporation of oleic acid in cholesteryl esters. This experimental design is probably an indirect method of measurement of cholesterol efflux and more a reflection of ACAT activity. In addition, the experiments were not performed in the presence of a cholesterol acceptor such as HDL. Also, it has previously been demonstrated that PGE 2 does not stimulate lysosomal or cytoplasmic cholesteryl ester hydrolytic activities.
128 '
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Our laboratory has found that cholesterol enrichment abolishes eicosanoid-dependent cholesterol efflux by reducing eicosanoid stimulation of lysosomal cholesteryl ester hydrolase. Van Sickle and Nasjletti 196 have demonstrated that in cholesteryl ester-enriched macrophages, only a minor component (10% to 15%) of HDL-induced cholesterol efflux is eicosanoid dependent. The data suggest that in pathological states in which there is significant cholesteryl ester accumulation, eicosanoiddependent mechanisms of cholesterol removal may be less important than the effects of cholesterol substrate for removal by cholesterol acceptors in plasma and esteriflcation by ACAT.
Platelet-derived Growth Factor
There is accumulating evidence that the chemotactic and chemokinetjc properties of growth factors may depend upon endogenously synthesized eicosanoids. Platelets, endothelial cells, smooth muscle cells, and macrophages secrete PDGF, 7 -197 -204 which, in turn, stimulates smooth muscle cell proliferation. 4 -205 There is also increased production of PDGF by proliferative smooth muscle cells after vascular injury. 206 In fact, RNA transcripts of PDGF are increased in atheromatous 207 but not in normal regions of aorta.
208 Smooth muscle cells derived from atheromatous lesions are also more proliferative, 209 possibly due to increased PDGF in that location. PDGF is both chemotactic 210 and chemokinetic 211 for smooth muscle cells. The latter phenomenon may be mediated by endogenously synthesized lipoxygenase, but not cydooxygenase products of arachidonic acid, since ETYA, but not indomethacin, inhibited PDGF-induced cell migration.
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In addition, while serotonin alone stimulates PGI 2 release by smooth muscle cells, PDGF is synergistic with serotonin in stimulating smooth muscle cell PGI 2 synthesis.
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Therefore, at sites of platelet deposition or monocyte infiltration, eicosanoids may mediate the effect of PDGF on smooth muscle cell chemotaxis. Exogenously added, highly purified PDGF can stimulate cholesteryl ester hydrolysis and PGI 2 production in smooth muscle cells. 135 Aspirin pretreatment inhibited both the increase in lysosomal cholesteryi ester hydrolase activity and PGI 2 release in these smooth muscle cells. 136 These data suggest that endothelial cells may mediate cholesteryl ester hydrolysis in smooth muscle cells by elaboration of other soluble factors, including PDGF, which augment eicosanoid metabolism in these cells. 135 However, the ability of PDGF to stimulate eicosanoid production is controversial. In some studies, PDGF stimulated cellular eicosanoid production, 212 -215 whereas in others, PDGF had no effect.
216 -217 Callahan et al.
217
attribute the ability of PDGF to alter eicosanoid production in some mesenchymal cells to impurities in the preparations, thus accounting for discrepancies in the literature involving PDGF and eicosanoid production. Collectively, these data become even more controversial, since PDGF has been shown to up-regulate activity of the LDL receptor, and to possibly render the cell dependent upon cholesterol synthesis to effect the proliferative response to PDGF. 222 This is in contrast to fibroblast lines, where PDGF stimulates cholesteryl ester deposition in NIH 3T3 cells. 223 Thus, the role of eicosanoids as second messengers in response to PDGF at the cellular level remains unresolved and requires further elucidation because of the involvement of this arterial cytokine in the promotion of intimal hyperplasia during atherosclerosis.
Procoagulant Activities
Normally endothelial cells maintain a characteristic nonthrombotjc surface; secretory products from nonactivated cells include PGI 2 and tissue plasminogen activator and little, if any, plasminogen activator inhibitor. However, in response to inflammatory and coagulant stimuli such as lipopolysaccharide, endothelial cells proliferate 224 and synthesize pro-inflammatory cytokines, such as interieukin-1 (IL-1) (see below). In these activated endothelial cells, the balance between plasminogen activator and plasminogen activator inhibitor favors net procoagulant characteristics. 226 -228 This shift from anticoagulant to procoagulant activity allows more local thrombin generation at the site of thrombus generation. Thrombin promotes proliferation by endothelial cells 4 by activation of c-sis gene expression 199 ; agents that elevate cAMP formation also inhibit thrombin induced c-sis gene expression 200 and expression of the B-chain for PDGF. 202 In addition to activating endothelial cells, thrombin also stimulates endothelial cell eicosanoid generation. 229 - 230 Since endothelial cell-derived eicosanoids are antiproliferative, this activity may represent a mechanism by which these eicosanoids modulate procoagulant activity and endothelial mitogenic response to thrombin. However, thrombin has different effects on arterial smooth muscle cells. Thrombin does not promote smooth muscle cell proliferation 231 or stimulate smooth muscle cell eicosanoid synthesis. The direct effects of thrombin on smooth muscle cell cholesterol metabolism are unknown. However, thrombin may regulate these processes in smooth muscle cells indirectly by promoting endothelial cell eicosanoid generation.
Host Defense Mediators
Endothelial cells synthesize PGI 2 in response to, and potentiate the effect of, a variety of host defense mediators. These include bradykinin, LTC,,, complement, kallikrein, immune complexes, complement complexes, and histamine. 230 -232 - 238 These agents may, therefore, indirectly modulate smooth muscle proliferative capacity and regulation of the cholesteryl ester cycle via endothelial cell-derived eicosanoids. In addition, serotonin, 239 bradykinin, 240 and angiotensin 11240,241 m a y gigg directly stimulate smooth muscle cell eicosanoid generation. These agents have not been thought to be involved in processes controlling arterial cholesterol metabolism. However, since it is now known that eicosanoids clearly influence arterial cholesterol metabolism, the concept that host defense mediators may influence vascular cholesterol metabolism via endogenously synthesized eicosanoids should be considered, since atherogenesis is considered to be an inflammatory/proliferative response to injury.
lnterleukln-1
IL-1 is a pro-inflammatory cytokine elaborated by endothelial cells in response to lipopolysaccharide and other stimuli. 242 IL-1 promotes monocyte and neutrophil chemotaxis and diapedesis into the vessel wall 226 -243 and stimulates monocyte eicosanoid generation. 244 Monocyte adhesion and diapedesis is associated with increased endothelial cell permeability to plasma components, including LDL 245 and 0-VLDL into the vascular interstitium. This may be partly due to production of monocytk; chemcattractants. 248 - 247 These data indicate that IL-1 could be involved in the atherogenic process. It has recently been demonstrated that IL-1 can directly stimulate PGE 2 , PGI 2 , and PGF^ synthesis as well as proliferation of human smooth muscle cells.
111 Since IL-1-induced smooth muscle cell proliferation was augmented in the presence of cyclooxygenase inhibitors and inhibited by exogenous PGE, and PGE 2 , perhaps endogenously synthesized eicosanoids are antiproliferative or serve to control the proliferative effect of IL-1.
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Gonadal Steroids
Although men are at a greater risk for cardiovascular morbidity and mortality than women before menopause, 248248 the influence of gender on arterial cholesterol deposition is unknown. In addition, the influence of gender and gonadal steroids in improving cardiovascular risk is equivocal. 248 Indeed, no gender difference in human arterial eicosanoid synthesis has been identified; thus, further investigation in this area is required.
Heparin
Heparin is an endothelial cell and platelet product, which may maintain the smooth muscle cell contractile phenotype and inhibit smooth muscle cell proliferation. 250 - 256 This property appears to be dissociated from heparin's anticoagulant activity. 256 The mechanism of heparin's antiproliferative effect is not well understood, but may be due to its ability to maintain smooth muscle cells in the contractile phenotype, thus preventing smooth muscle cells to respond to mitogens and subsequently proliferate. 87 -88 There may be numerous cellular mechanisms by which heparin inhibits the proliferation of arterial smooth muscle cells. Heparin decreases the number of epidermal growth factor (EGF) receptors on smooth muscle cells, 257 suggesting that heparin reduces the ability of smooth muscle cells to respond to EGF stimulation. Heparin's ability to inhibit smooth muscle cell proliferation may also be mediated by activation of transforming growth factor-beta, a known inhibitor of smooth muscle cell proliferation. 258 Heparin also inhibits 1,4,5-trisphosphate-induced calcium release from smooth muscle cells, 259 suggesting that heparin may inhibit the effects of agonist-induced activation of the phosphoinositol pathway in smooth muscle cells. These data are significant since phospholipase C exists in arterial smooth muscle cells and appears to be important in the modulation of receptor-coupled PIP 2 synthesis and calcium mobilization. 260 Furthermore, inositol lipids have been implicated in the regulation of cell proliferation via the phosphorylation of tyrosine kinases (for a review of this subject, see reference 261). However, no data are currently available on alterations of phosphoinositol metabolism in hyperiipidemia or atherosclerosis. It is possible that the mitogenic effects of PIP 2 are normally regulated by endogenous eicosanoid production, and that the loss of heparin effect during lipid-enrichment may favor cell proliferation.
There is anecdotal, unpublished data suggesting that heparin's antiproliferative effect may also be mediated by its ability to stimulate eicosanoid production. However, the documented effect of heparin on smooth muscle cell eicosanoid generation is unknown, although the effects of heparin on smooth muscle cell proliferation are similar to those of PGI 2 . Interestingly, postconfluent smooth muscle cells synthesize an antiproliferative heparan sulfate whose effect on smooth muscle cell eicosanoid generation is also unknown. 294 These data suggest that endothelial cells may maintain smooth muscle cells in the contractile phenotype not only by synthesizing eicosanoids such as PGI 2 , but also by synthesizing heparin and other heparinlike molecules. Thus, redundant systems appear to maintain smooth muscle cells in a physiologically quiescent state. These data also imply that reductions in heparin biosynthesis may predispose to smooth muscle cell modulation to the synthetic phenotype and increased responsiveness to mitogens. The fact that heparin and PDGF are found within platelets suggests that the smooth muscle response to mitogens delivered by platelets is regulated by the intrinsic antiproliferative effects of heparin as well as by endogenously synthesized eicosanoids.
In addition to affecting smooth muscle cell proliferative capacity, heparin may also affect cellular cholesterol metabolism. Heparin has the ability of binding to plasma lipoproteins, particularly LDL 262 Heparin-LDL complexes have been isolated from atheromata 263 -264 -265 ; such complexes in the presence of other connective tissue components, such as fibronectin and collagen, may promote cholesterol accumulation in macrophages by binding and intemalization via the scavenger receptor. 266 -287 It has been postulated that such interactions are one potential mechanism of increased cholesteryl ester deposition in plaque areas. This phenomena has not been evaluated in smooth muscle cells, nor has an eicosanoid-dependent component of this process been evaluated.
Thus, heparin has a multiplicity of effects that may be important in maintaining smooth muscle cell phenotype, and that may provide a potential mechanism for macro-phage clearance of LDL lipid. Thus, the role of heparin in the atherogenic process is not complete, and the role of eicosanoids in mediating such effects requires further investigation.
Dietary Modification of Elcosanold Formation-Marine Llplds
There is a developing substantive body of data on the effects of fish oils in altering the clinical sequelae of atherosclerosis. This information has been generated in part by observations that diets high in eicosapentaenoic (EPA) and docosahexaenoic acid (both found in relative abundance in fish oils), appear to be protective in coronary vascular disease in certain populations 268 -269 ' 270 (see references 271 to 274 for reviews). The mechanism of this effect appears to be caused by reduced platelet function, such as decreases in platelet aggregation, TxA 2 formation, and PDGF release. 275 -278 This may be due to the fact that TxA 3 (the EPA homolog of TxA 2 ) possesses significantly less activity than TxA 2 , while PGI 3 possesses similar biological properties to PGI 2 . In addition, these fatty acids may also inhibit arterial smooth muscle cell proliferation by inhibiting endothelial cell synthesis of PDGF. 279 EPA may also reduce plasma lipids, principally triglycerides, with equivocal changes in LDL or HDL levels, 280 -283 and EPA may increase fecal excretion of neutral and acid sterols. 284 However, the role of EPA and other marine lipids on arterial cholesterol metabolism is undefined since few laboratories are actively pursuing this area. Presently, we know that the accumulating results of EPA studies are equivocal. Adverse effects by EPA include alterations in serum lipids and Increased dietary requirement for supplemental antjoxidants, such as vitamins E and C. For this reason, it remains to be seen if marine lipids will modulate the interaction of lipoproteins within the vessel wall, as well as modulation of the cholesteryl ester cycle, to promote an antiatherogenic environment It also remains to be established if this potential benefit is greater than the possible risks of free radical-mediated damage to membranes and other cell constituents.
Conclusions
Eicosanoids are thought to play a role in the maintenance of vessel wall homeostasis and to act either cooperatively or antagonistically to mediate or modulate external agonists. Endogenously synthesized eicosanoids can regulate the effects of vasodilators such as bradykinin and can antagonize the effects of vasoconstrictors, such as angiotensin. 285 The data discussed in this article suggest that eicosanoids such as PGI 2 synthesized by the blood vessel wall serve to restore smooth muscle cells to the differentiated, quiescent state. In addition, this eicosanoid can maintain a low, cell cholesterol content. This is accomplished by promoting net cellular cholesteryl ester hydrolysis by stimulation of the activities of the cholesteryl ester hydrolytic enzymes while inhibiting ACAT. Eicosanoids derived from adjacent endothelium as well as from inflammatory cells, such as neutrophils and macrophages, may also serve to stimulate smooth muscle cells into a proliferative state as a response to injury. 288 reductions in eicosanoid synthetic capacity during the course of a chronic inflammatory state (induced by hyperlipidemia, viral infection, or hemodyamic stress) may also promote cholesterol accumulation superimposed upon cellular proliferation in response to growth factors and other cytokines. This could result in the eventual formation of atherosclerotic plaques. We have summarized this basic concept in Figure 2 . Thus, in addition to their possible use as vasodilators in vascular disorders such as pulmonary hypertension 287 and the prolongation of allograft survival after cardiac and renal transplantation, 288 it has been suggested that stable eicosanoid analogues that remain metabolically active be used as a therapeutic modality to inhibit intimal smooth muscle cell proliferation and facilitate mobilization of cholesteryl ester in smooth muscle cells in conditions of reduced endogenous eicosanoid generation during atherogenesis. 289 - 292 It remains to be seen whether administration of such eicosanoid analogues (cydooxygenase or lipoxygenase metabolites) can affect the progression of human coronary atherosclerosis or peripheral vascular disease under conditions of moderate to high blood lipid levels. 
